GSK’s Overhaul Undermined by Decline From Older Medicines

GSK Plc’s older respiratory medicines showed lackluster sales in the first quarter, leaving HIV and cancer drugs to drive profit growth.

The shares fell as much as 3.5% in early London trading, trimming the year’s gain to about 8%. That was despite GSK reporting higher-than-expected profit in a statement WednesdayBloomberg Terminal as investors focused on the weakness in its general medicines divisions.